Antibodies directed against amyloid-beta peptide and methods using same
First Claim
1. A method for treating a disease characterized by aberrant deposition of a protein in the brain of a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to the protein or an aggregated form of the protein, wherein the antibody comprises an Fc region having impaired effector function.
1 Assignment
0 Petitions
Accused Products
Abstract
Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer'"'"'s disease and Aβ peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer'"'"'s disease and Aβ peptide associated diseases are also described.
-
Citations
78 Claims
- 1. A method for treating a disease characterized by aberrant deposition of a protein in the brain of a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to the protein or an aggregated form of the protein, wherein the antibody comprises an Fc region having impaired effector function.
-
28. A method for treating a disease associated with aberrant deposition of β
- -amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
-amyloid peptide or an aggregated form of a β
-amyloid peptide, wherein the antibody comprises an Fc region with a variation from a naturally occurring Fc region, wherein the variation results in impaired effector function. - View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
- -amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
-
51. An antibody comprising a heavy chain variable region comprising:
-
(a) a CDR1 region shown in SEQ ID NO;
3;
(b) a CDR2 region shown in SEQ ID NO;
4; and
(c) a CDR3 region shown in SEQ ID NO;
5, wherein L1 is L, V, or I;
wherein Y2 is Y or W;
wherein S3 is S, T, or G;
wherein L4 is L, R, A, V, S, T, Q, or E;
wherein V6 is V, I, T, P, C, Q, S, N, or F and wherein Y7 is Y, H, F, W, S, I, V, or A.wherein the antibody specifically binds to an Aβ
peptide. - View Dependent Claims (52, 53, 54, 64, 65, 66, 67, 72, 73, 74, 75, 76, 77, 78)
-
-
55. An antibody comprising a light chain variable region comprising:
-
(a) a CDR1 region shown in SEQ ID NO;
6, wherein Y8 is Y, A, or H;
wherein A11 is A or S; and
wherein K12 is K or A;
(b) a CDR2 region shown in SEQ ID NO;
7; and
(c) a CDR3 region shown in SEQ ID NO;
8, wherein L1 is L, M, N, C, F, V, K, S, Q, G, S;
wherein G3 is G, S, or T;
wherein T4 is T or S;
wherein H5 is H or L;
wherein Y6 is Y, P, A, W, Q, M, S, or E;
wherein V8 is V, L, K, H, T, A, E, or M; and
wherein L9 is L, I, T, S, or V;
wherein the antibody specifically binds to an Aβ
peptide. - View Dependent Claims (56, 57, 58, 59, 60, 61, 62, 63, 68, 69, 70, 71)
-
Specification